With the premise that COVID-19 may be impossible to eradicate, medical researchers are trying to find treatment options that will allow us to live with the virus and treat it in the most effective way possible. ViroGates, a Danish EIC-funded company, is trialling an innovative solution that measures a patient’s blood level of suPAR to identify if there is a risk of severe respiratory failure. The trial results have recently shown a very positive outcome, with a 64% improvement in overall patient outcome from COVID-19 patients.
The controlled trial SAVE-MORE runs in over 600 hospitalised patients, assessing the effectiveness of the anakinra treatment guided by suPAR (a protein in the blood that reflects immune activation). The study’s interim results indicated a 64% improvement in overall patient outcome from COVID-19 patients. The overall results showed significant prevention of death and respiratory failure and an increase in the number of patients discharged from the hospital with no evidence of COVID-19 infection.
Mark Christian Hvidberg da Silva, CFO of ViroGates, said: “We are hopeful that this treatment will save lives and reduce healthcare costs in Europe and beyond. Still, most importantly, all of this had not been possible without the Horizon 2020 grant that partly funded the initial SAVE trial. We believe it is an excellent example of the impact the programme has!”
Based on the success of the achieved interim results, a new randomised controlled trial study was initiated. ViroGates also intends to participate in discussions with regulatory authorities in the light of these positive results.
ViroGates has received a Phase 2 Grant from the European Innovation Council to bring to the market the suPARnostic test to improve prognosis and care for patients with COVID-19.
DISCLAIMER: This information is provided in the interest of knowledge sharing and should not be interpreted as the official view of the European Commission, or any other organisation.